San Diego, Research Triangle, San Francisco, Boston, Boulder. What do these high-tech hotspots have in common? The engine of the economic growth in these regions is the intellectual property coming out of academic and other research institutions.
The first step in translation of ideas and inventions into commercial reality is the university technology transfer office. The entrepreneur should understand the goals of the academic institution and the restrictions placed on technology transfer offices before entering negotiations.
At this BioE2E event, experienced panelists from technology licensing offices and entrepreneurs will discuss the process of technology transfer from academia to the entrepreneur.
Topics will include: (1)
Overview of two perspectives of technology transfer a.
Academic perspective b.
Entrepreneur perspective (2)
Sources of information on academic licensing (3)
The deal negotiation process (4) Institution to institution variation (5) Types of payment: royalties, cash, equity (6) Licensing: exclusive, non-exclusive, options
on new inventions (7) Long term obligations to commercialize the
technology (8)
Future of technology transfer – emergence and disappearance of alternative channels for technology licensing
Networking session will follow.
Expected Panelists:
|
Kenneth
A. Clark
|
|
| Kenneth A. Clark is Managing Partner of Wilson Sonsini Goodrich & Rosati's Technology Transactions Group, which specializes in transactions involving products and/or technology, from strategic alliances to license, development, supply and distribution arrangements. Ken has negotiated more than 40 major strategic alliance transactions in both the information technology and life sciences industries. He also regularly represents companies in spin-outs and core technology licenses, as well as other technology transactions. From 1992 to 1993, Ken served as Vice President, General Counsel & Secretary of Maxtor Corporation, then a $1.5 billion disk drive manufacturer. He received his undergraduate degree from Vanderbilt University and his law degree from the University of Texas. | |
|
Joel
B. Kirschbaum, Ph.D.
|
|
| Joel is Director and Senior Technology Portfolio Manager for the UCSF Office of Technology Management. Joel has been with the office since its inception in July, 1996. He has eleven years of experience as a senior R&D manager in the biotechnology industry and twelve years of experience as an independent R&D consultant and interim R&D manager for clients comprising leading venture capitalists, entrepreneurs, biotechnology firms, and pharmaceutical companies. Previously, he spent fourteen years as an academic researcher in genetics, biochemistry, and molecular biology including a faculty appointment at Harvard Medical School. He received a Ph.D. in Biochemistry and Molecular Biology from Harvard University (under James D. Watson) and earned a B.A. in Chemistry from Pomona College (magna cum laude, Phi Beta Kappa). | |
|
Michael
Kope
|
|
| Mike is Director of Corporate Development for MedImmune, Inc., serving the MedImmune Vaccines unit formerly known as Aviron. He came to Aviron a few years after having licensed the company its core FluMistTM technology in 1995 from the University of Michigan, where he served as the University's Intellectual Property Counsel and technology transfer representative. With deep experience on both sides of the fence, Mike has negotiated a broad range of business acquisition and partnership agreements, designed strategies for technology protection and promotion in many fields of research, written a variety of university technology policies, served on faculty conflict of interest committees, and facilitated a number of successful university spin-offs. He received his JD from University of Michigan in 1990. | |
|
Barclay
Kamb
|
|
| Mr Kamb's practice focuses on the representation of biotechnology and medical device companies, with particular expertise in transactions involving intellectual property. Much of his practice is devoted to negotiating and drafting corporate partnership agreements, licensing arrangements, strategic alliances, joint venture agreements and other sophisticated technology transactions. Mr. Kamb received a B.S. degree in Biology from Stanford University in 1983. He conducted post-graduate studies in biology at the Massachusetts Institute of Technology under a National Science Foundation Fellowship award. He received a J.D. degree in 1988 from the Boalt Hall School of Law, University of California at Berkeley, where he was awarded the Prosser Prize in Contracts. Mr. Kamb also served as an Associate Editor on the California Law Review. |